Statistics

Total Visits

Views
Phase IB/II study of the HSP90 inhibitor AUY922, in combination with trastuzumab, in patients with HER2+ advanced breast cancer53

Select a period of time:

Number of views in the range

Views
Phase IB/II study of the HSP90 inhibitor AUY922, in combination with trastuzumab, in patients with HER2+ advanced breast cancer9

Views

Views
November 20250
December 20251
January 20260
February 20260
March 20264
April 20263
May 20261
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States3
China2
Colombia1
Ethiopia1
Senegal1
Tunisia1
 

Top cities views

Views
Addis Ababa1
Dakar1
Los Angeles1
Nabeul1
Santiago de Cali1